Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1

Life Sciences

Volumn 79, Issue 25, 2006, Pages 2370-2381

  Starzec, Anna ^a   Vassy, Roger ^a   Martin, Antoine ^b   Lecouvey, Marc ^c   Di Benedetto, Mélanie ^a   Crépin, Michel ^d   Perret, Gérard Y ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

^c Laboratoire de Chimie Structurale Biomoléculaire   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Angiogenesis; KDR; Neuropilin 1; Tumor growth; VEGF 165

Indexed keywords

ALANYLTHREONYLTRYPTOPHYLLEUCYLPROLYLPROLYLARGININE; HEPARIN; MATRIGEL; NEUROPILIN 1; PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CHO CELLS; COCULTURE TECHNIQUES; CRICETINAE; CROSS-LINKING REAGENTS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; HUMANS; IMMUNOENZYME TECHNIQUES; IODINE RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; PEPTIDE FRAGMENTS; PROTEIN BINDING; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 33751091501     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.08.005     Document Type: Article

References (41)

1. Alroy J., Goyal V., and Skutelsky E. Lectin histochemistry of mammalian endothelium. Histochemistry 68 (1987) 603-607
2. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., and Mercurio A.M. Vascular endothelial growth factor is a autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Research 61 (2001) 5736-5740
3. Bachelder R.E., Wendt M.A., and Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Research 62 (2002) 7203-7206
4. Bagheri-Yarmand R., Kourbali Y., Rath A.M., Vassy R., Martin A., Jozefonvicz J., Soria C., Lu H., and Crépin M. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB-435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Research 59 (1999) 507-510
5. 165 induces apoptosis of neuropilin-1-expressing breast tumour cells. British Journal of Cancer 92 (2005) 328-333
6. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nature Reviews. Cancer 3 (2003) 401-410
7. Bernatchez P.N., Soker S., and Sirois M.G. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. Journal of Biological Chemistry 274 (1999) 31047-31054
8. Binétruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouêt J., Derbin C., Perret G., and Mazié J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO Journal 19 (2000) 1525-1533
9. Bishop E.T., Bell G.T., Bloor S., Broom I.J., Hendry N.F.K., and Wheatley D.N. An in vitro model of angiogenesis: basic features. Angiogenesis 3 (1999) 335-344
10. Cheng L., Jia H., Löhr M., Bagherzadeh A., Holmes D.I.R., Selwood D., and Zachary Y. Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. Journal of Biological Chemistry 279 (2004) 30654-30661
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 (1995) 27-31
12. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
13. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
14. Holmren L., O'Reilly M.S., and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1 (1995) 149-153
15. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nature Medicine 9 (2003) 669-676
16. Grunstein J., Masbad J.J., Hickey R., Giordano F., and Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Molecular and Cellular Biology 20 (2000) 7282-7291
17. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. Journal of Biological Chemistry 267 (1992) 26031-26037
18. Inoue M., Hager J.H., Ferrara N., Gerber H.P., and Hanahan D. VEGF-A has critical role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cells 1 (2002) 193-202
19. Kawakami T., Tokunaga T., Hatanaka H., Kijima H., Yamazaki H., Abe Y., Osamura Y., Inoue H., Ueyama Y., and Nakamura M. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95 (2002) 2196-2201
20. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., and Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. Journal of Biological Chemistry 271 (1996) 7788-7795
21. Latil A., Bièche I., Pesche S., Valéri A., Fournier G., Cussenot O., and Lidereau R. VEGF overexpression in clinically located prostate tumors and neuropilin-1 overexpression in metastatic forms. International Journal of Cancer 89 (2000) 167-171
22. Lee C.C., Kreusch A., McMullan D., Ng K., and Spraggon G. Crystal structure of the human neuropilin-1 b1 domain. Structure 11 (2003) 99-108
23. Malavaud B., Tack I., Jonca F., Praddaude F., Moro F., Ader J.L., and Plouet J. Activation of Flk-1/KDR mediates angiogenesis but not hypotension. Cardiovascular Research 36 (1997) 276-281
24. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., and Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b23 domain. Journal of Biological Chemistry 277 (2002) 24818-24825
25. Mattsson G., Carlsson P.O., Olausson K., and Jansson L. Histological markers for endothelial cells in endogenous and transplanted rodent pancreatic islets. Pancreatology 2 (2002) 155-162
26. Miao H.Q., Lee P., Lin H., Soker S., and Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB Journal 14 (2000) 2532-2539
27. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 13 (1999) 9-22
28. Oh H., Takagi H., Otani A., Koyama S., Kemmochi S., Uemura A., and Honda Y. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 383-388
29. Parikh A., Liu W.B., Fan F., Stoeltzing O., Reinmuth N., Bruns C.J., Bucana C.D., Evans D.B., and Ellis L.M. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98 (2003) 720-729
30. Parikh A.A., Fan F., Liu W.B., Ahmad S.A., Stoeltzing O., Reeinmuth N., Bielenberg D., Bucana C.D., Klagsbrun M., and Ellis L.M. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. American Journal of Pathology 164 (2004) 2139-2151
31. 99mTc-labelled anti-VEGF peptide targeting neuropilin-1. Nuclear Medicine and Biology 31 (2004) 575-581
32. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Aimone L., Klein-Szanto A., Herbert J.M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., and Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Research 63 (2003) 5978-5991
33. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
34. 165-receptor binding. Journal of Cellular Biochemistry 85 (2002) 357-368
35. Stephenson J.M., Banerjee S., Saxena N.K., Cherian R., and Banerjee S.K. Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. International Journal of Cancer 101 (2002) 409-414
36. Tao Q., Spring S.C., and Terman B.I. Characterization of a new alternatively spliced neuropilin-1 isoform. Angiogenesis 6 (2003) 39-45
37. Vauquelin G., Van Liefde I., and Vanderheyden P. Models and methods for studying insurmountable antagonism. Trends in Pharmacological Sciences 23 (2002) 514-518
38. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. Journal of Biological Chemistry 269 (1994) 26988-26995
39. Wang L., Zeng H., Wang P., Soker S., and Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. Journal of Biological Chemistry 278 (2003) 48848-48860
40. 121. Journal of Biological Chemistry 276 (2001) 25520-25531
41. Workman P., Twentiman P., Balkwill F., Balmain A., Chaplin D., Double J., Embleton J., Newell D., Raymond R., Stables J., Stephens T., and Wallace J. United Kingdom co-ordinating committee on cancer research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. British Journal of Cancer 77 (1998) 1-10